We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is highly synergistic to our Rare Disease business. We believe our proven ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

ANI Pharmaceuticals (NASDAQ:ANIP) announced that following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06% ...

"With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased to bring another limited-competition ...

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences.

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera ...